<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859285</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 15-18</org_study_id>
    <nct_id>NCT02859285</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women</brief_title>
  <official_title>Sexual Function in Postmenopausal Women: A Double Blinded, Randomized Pilot Study Evaluating the Effects of Topical Clitoral Estradiol Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProHealth Care, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProHealth Care, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about sexual function in postmenopausal women
      and to determine whether the use of topical clitoral application of estradiol improves
      women's libido, arousal, and orgasmic ability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>19 point validated Female Function Index.</measure>
    <time_frame>Baseline then change over time at week 4,8,12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>36 point RAND health survey.</measure>
    <time_frame>Baseline then change over time at week 4,8,12.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>10 point Likert scale</measure>
    <time_frame>Baseline then change over time at week 4,8,12.</time_frame>
    <description>Visual Analog Scale to measure improvement in libido, arousal and orgasm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypoactive Sexual Desire Disorder</condition>
  <arm_group>
    <arm_group_label>Estradiol vulvar cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo vulvar cream</intervention_name>
    <arm_group_label>Placebo cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Estradiol vulvar cream</intervention_name>
    <arm_group_label>Estradiol vulvar cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sexually active postmenopausal women of any age with complaint of vulvar and/or
             vaginal atrophy who also complain of bothersome decreased libido, and/or arousal,
             and/or orgasmic dysfunction

        Exclusion Criteria:

          -  Not sexually active with a partner or an arousal device

          -  Uncontrolled diabetes as defined by having a consistent blood sugar level of over 100
             mg/dL

          -  Uncontrolled hypertension as defined by an average systolic blood pressure ≥140 mmHg
             or an average diastolic blood pressure ≥90 mmHg, among those with hypertension

          -  Allergic to estradiol

          -  Contraindications to estradiol such as undiagnosed abnormal genital bleeding;
             known/suspected or history of breast cancer; known/suspected estrogen-dependent
             neoplasm; active deep vein thrombosis, pulmonary embolism; active or recent stroke or
             myocardial infarction; liver dysfunction or disease

          -  Spanish speaking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarit Aschkenazi, MD</last_name>
    <role>Study Director</role>
    <affiliation>ProHealth Care, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Waukesa Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arousal</keyword>
  <keyword>Orgasm</keyword>
  <keyword>Clitoral</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Post Menopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

